Core Viewpoint - The article emphasizes that AI will not replace traditional Chinese medicine (TCM) but rather enhance the capabilities of TCM practitioners who can effectively utilize AI tools [6][21]. AI in Traditional Chinese Medicine - AI has the potential to assist in diagnosing and treating patients by providing reference prescriptions based on symptoms, as demonstrated by tools like DeepSeek [4][5]. - The consensus among industry professionals is that the future of TCM lies in practitioners who can leverage AI rather than AI replacing practitioners [6][21]. Current Applications of AI in TCM - Young TCM doctors reported limited use of AI during face-to-face consultations, primarily utilizing it for administrative tasks like creating teaching materials and work summaries [9]. - AI is seen as a tool for analyzing complex cases and expanding diagnostic thought processes, particularly in Western medicine contexts [10]. Challenges in AI Implementation - The complexity of TCM's theoretical framework poses challenges for AI, as it requires structured data for effective training, which is often lacking [11]. - AI struggles with the "four diagnostic methods" (observation, listening, inquiry, and pulse-taking) essential in TCM, leading to potential misdiagnoses [12]. Future Directions for AI in TCM - AI can improve patient-doctor matching by assessing TCM practitioners' capabilities and guiding patients to suitable doctors based on their symptoms [17]. - In the diagnostic and treatment phases, AI can assist in analyzing patient information and drafting medical documents, allowing doctors to focus more on patient interaction [18]. AI's Role in Enhancing TCM Practice - The development of AI tools aims to elevate the diagnostic capabilities of TCM, with products like AI-assisted consultation and digital representations of renowned TCM practitioners being explored [19]. - AI can also facilitate patient follow-ups and health management, enhancing the overall patient experience [20]. Conclusion - The article concludes that the integration of AI into TCM is not about replacement but about collaboration, where AI acts as a supportive tool for practitioners to improve their practice and patient outcomes [21].

Core Insights - The article highlights the significant role of AI in transforming healthcare through the establishment of the Tianjin Digital Health Community, led by Weiyi Holdings, which has become a model for AI healthcare development in China [1][2][5] Group 1: Company Overview - Weiyi Holdings has positioned itself as the largest AI healthcare solution provider in China, with AI medical revenue accounting for 79.21% of total revenue in the first half of 2024, amounting to 1.44 billion yuan [1][6] - The company has seen a consistent increase in revenue from AI medical services, with figures rising from 228 million yuan in 2021 to 1.44 billion yuan in the first half of 2024 [6][7] Group 2: AI Healthcare Model - The Tianjin Digital Health Community, initiated in 2020, has expanded from 266 to 278 medical institutions, including primary, secondary, and tertiary hospitals, showcasing a collaborative approach to healthcare [5][7] - AI has been integrated into various healthcare processes, enhancing the efficiency and accuracy of diagnosis and treatment, with AI doctors achieving a 99.97% compliance rate in reminding doctors about unreasonable prescriptions [5][6] Group 3: Health Outcomes - The implementation of AI in the Tianjin Digital Health Community has led to significant improvements in patient health metrics, such as an increase in the diabetes management success rate from 17.8% to 44.2% [6] - The community has also seen a rise in outpatient visits by 23% to 50%, indicating increased patient engagement and trust in the healthcare services provided [6] Group 4: Future Expansion Plans - Weiyi Holdings plans to replicate the Tianjin model in other cities, having already signed strategic agreements with governments in Guiyang and Yinchuan, with further expansions anticipated in Shanghai and other major cities [7] - The company aims to prioritize partnerships in cities with strong governmental support for healthcare reform, focusing on enhancing healthcare accessibility and quality for patients [7]

Summary of Conference Call Records Company Overview - **Company**: Ping An Health Medical Technology Co., Ltd. - **Key Executives**: Wu Jun (President), Zhang Ruoqi (CFO) Industry Insights - **Industry**: Healthcare and Insurance - **Focus Areas**: Home healthcare services, AI in healthcare, strategic partnerships, and product innovation Key Points and Arguments Strategic Progress - The company has made significant strides in enhancing its AI capabilities, achieving 24/7 response times with AI digital doctors, and signing over 2,000 expert doctors in 2024 [1][3] - The strategic focus for 2024 includes deepening strategic partnerships, enhancing service capabilities, and driving technological innovation [2][3] Financial Performance - The company reported total revenue of 4.811 billion yuan, a year-on-year increase of approximately 3%, marking a turning point in performance [10] - The number of corporate clients served reached 2,049, a 35.9% increase year-on-year, with corporate income growing by 69.7% [5] - Adjusted net profit reached 158 million yuan, reflecting a significant improvement from previous periods [13] Service Expansion - Home healthcare services have expanded to cover over 150 suppliers, establishing industry standards for rehabilitation and elderly care [2] - The company has upgraded its service network from three to four channels, enhancing service delivery and customer experience [7][22] AI and Technology Integration - The company has developed a proprietary AI model, "Ping An Yibo Tong," which has been validated through various applications, improving service efficiency and accuracy [9][20] - AI has significantly enhanced the efficiency of medical services, with diagnostic accuracy reaching 95% and chronic disease management improvement rates at 90% [9] Customer Engagement and Satisfaction - The average annual service frequency for family doctors reached 5 times, indicating growing user acceptance [6] - The company has implemented a proactive approach to customer service, shifting from post-event claims to pre-emptive health management [36] Market Position and Future Outlook - The company aims to leverage its unique position within the Ping An Group to enhance its service offerings and market penetration [25][32] - The focus on elderly care and home services is expected to drive future growth, with a significant market potential identified [27][29] Cost Management and Profitability - Overall expenses decreased by 6.23 billion yuan, with an improved efficiency ratio of 35.2%, down 14.4 percentage points year-on-year [11] - The company anticipates continued improvement in profitability as operational efficiencies are realized [14][40] ESG Commitment - The company is committed to sustainable development, integrating ESG principles into its long-term strategy [14][15] Additional Important Insights - The company is actively exploring partnerships and acquisitions to enhance its service capabilities and market reach [34] - There is a strong emphasis on integrating healthcare services with financial products to create a comprehensive service ecosystem [26][32] This summary encapsulates the key insights and developments discussed during the conference call, highlighting the company's strategic direction, financial performance, and market positioning within the healthcare industry.

近日，2025京东健康体重管理行业峰会在北京举行。会上，京东健康邀请中华医学会内分泌学会常委、 同济大学医学院肥胖症研究所所长曲伸，以及来自北京大学第一医院、中日友好医院的医生专家，围绕 肥胖症的长期管理，以及构建"防-治-管"三位一体的科学减重全周期支持体系等话题展开深入讨论。京 东健康相关负责人表示，作为国内首批上线体重管理门诊的互联网医院，京东互联网医院减重门诊上线 1个月以来，已帮助多位用户实现科学减重，用户服务满意度达到99%。 常饮食非常不规律，日均步数也不足2000步，还经常熬夜晚睡。在专业营养师一对一的指导下，他开始 调整饮食结构和生活方式，并且配合运动和补充营养素来提升身体代谢。在短短10天内，杨先生就成功 减重了2.5公斤，体脂率下降了1.4%，肌肉率提升了0.9%，BMI下降了1.0%。 体重管理不仅是体重秤上数字的改变，更是健康生活方式的重塑，因此肥胖问题的解决不仅需要医疗体 系的支持，还需要社会各界的共同努力。未来，京东健康将继续携手行业伙伴积极响应《"体重管理 年"活动实施方案》政策要求，发挥供应链优势与医疗服务资源，构建更加开放、协同、共赢的健康生 态，共同打造科学减重的服务范本 ...

Core Viewpoint - JD Health collaborates with the Civil Aviation Administration of China to enhance smart healthcare and patient services, aiming to improve hospital operational efficiency and patient experience [1][2]. Group 1: Collaboration Details - The partnership focuses on multiple areas including smart healthcare, supply chain services, and patient services [1]. - JD Health will leverage its strengths in pharmaceutical supply chain, medical big data, and artificial intelligence to provide comprehensive technical support to the Civil Aviation General Hospital [1]. - The collaboration aims to create an AI-based patient service system, utilizing JD Health's large model product, JD Zhuoyi (JOY DOC), to offer solutions like intelligent triage and pre-appointment registration [1]. Group 2: Service Innovations - The initiative promotes a new model of healthcare that combines online and offline services, enhancing convenience for patients [2]. - JD Health will provide online platforms, technical services, and operational support to the Civil Aviation General Hospital, including home nursing services such as intravenous blood collection and post-operative care [1][2]. - The collaboration will also explore the integration of JD Logistics' supply chain capabilities to offer comprehensive pharmaceutical logistics services, ensuring efficient access to necessary medications and materials [2]. Group 3: Future Directions - Both parties plan to deepen their cooperation and explore more innovative models and services to provide convenient, efficient, and high-quality healthcare services [2].

Group 1 - The core index of the China Securities Internet Medical Theme Index (CS Internet Medical, 930720) opened lower but rose, closing at 2514.46 points with a trading volume of 6.017 billion yuan [1] - Over the past month, the CS Internet Medical Theme Index has decreased by 12.73%, increased by 15.90% over the past three months, and has risen by 5.70% year-to-date [1] - The index reflects the overall performance of representative companies providing hardware, software, or services for medical informationization and intelligence [1] Group 2 - The top ten weighted companies in the CS Internet Medical Theme Index are: Yifeng Pharmacy (6.65%), Daclin (6.44%), Laobaixing (6.21%), Wandong Medical (5.53%), Haier Biomedical (5.48%), Jiuzhoutong (5.44%), Yixintang (5.37%), Aier Eye Hospital (5.33%), Yuyue Medical (5.28%), and Lepu Medical (5.17%) [1] - The market share of the CS Internet Medical Theme Index holdings is 51.03% from the Shenzhen Stock Exchange and 48.97% from the Shanghai Stock Exchange [1] - The industry composition of the index holdings shows that 70.41% is in pharmaceuticals and healthcare, 25.78% in information technology, and 3.81% in communication services [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day after the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] Group 4 - Public funds tracking the CS Internet Medical Index include: Huatai-PineBridge China Securities Internet Medical A and Huatai-PineBridge China Securities Internet Medical C [3]

Core Insights - The report highlights the performance of the Hong Kong stock market, with the Hang Seng Index at 20,682, reflecting a 2.1% increase year-to-date [3]. - The report indicates that the market is currently influenced by geopolitical tensions, particularly between the US and China, which has led to increased volatility and a rise in gold prices [11][12]. - The report notes that the recent performance of specific stocks within the Hang Seng Index shows significant variances, with JD Health (6618) leading with an 8.2% daily increase and a 15.7% year-to-date increase [4]. Market Overview - The Hang Seng Index has seen a trading volume of HKD 3,955.3 billion, with a price-to-earnings (PE) ratio of 9.2 and a price-to-book (PB) ratio of 0.98 [5]. - The H-share index recorded a trading volume of HKD 1,659.8 billion, with a PE ratio of 8.6 and a PB ratio of 0.91 [5]. - The technology index had a trading volume of HKD 1,283.1 billion, with a PE ratio of 19.8 and a PB ratio of 2.70 [5]. Stock Performance - The report identifies the top three performing stocks in the Hang Seng Index: JD Health (6618) with a price of HKD 32.50, Lenovo Group (0992) at HKD 8.03, and BYD Electronics (0285) at HKD 31.05 [4]. - Conversely, the worst performers include China Shenhua (1088) at HKD 30.35, New Oriental Education (9901) at HKD 33.60, and Xinao Gas (2688) at HKD 60.00 [4]. Economic Indicators - The report mentions that the People's Bank of China maintained the 5-year Loan Prime Rate (LPR) at 3.60% and the 1-year LPR at 3.10% [11]. - The US Federal Reserve decided to keep interest rates unchanged in March, with expectations of two rate cuts totaling 0.5% later in the year [11]. - The report also highlights the recent inflation data from the US, with the March Consumer Price Index (CPI) at 2.4%, below the expected 2.5% [15]. Company Analysis - The report discusses the strong performance of Zhaojin Mining (1818.HK), which reported a revenue increase of 37.12% year-on-year to RMB 11.55 billion, with a net profit increase of 112% to RMB 1.45 billion [26]. - The company achieved a total gold production of 26,449.73 kg, a year-on-year increase of 7.15%, driven by acquisitions and increased processing capacity [26][27]. - The report notes that Zhaojin Mining's current price of HKD 15.06 reflects a trailing twelve months (TTM) PE ratio of approximately 33.69, which is lower than the 10-year average of 60.65, indicating an attractive valuation [27].

Core Viewpoint - The article highlights the importance of comprehensive management for constipation and digestive system diseases, emphasizing the role of JD Health in providing accessible and professional health services for patients [1][2][4]. Group 1: Disease Prevalence and Impact - Constipation affects 4% to 6% of adults in China, with the prevalence increasing with age, reaching up to 22% in individuals over 60 years old [2]. - Long-term constipation can lead to serious health issues, including abdominal pain, anal diseases, and cardiovascular problems [2]. Group 2: Comprehensive Health Services - JD Health advocates for a full-cycle management approach for constipation, offering services from prevention and diagnosis to treatment and rehabilitation [2]. - The platform provides extensive educational content on symptoms, causes, prevention, and treatment of digestive system diseases, presented in an easy-to-understand format [2]. Group 3: Diagnostic and Treatment Support - JD Health integrates online and offline resources to facilitate convenient online consultations with top digestive specialists from renowned medical institutions [2]. - The company offers a wide range of medications and personalized medication guidance from professional pharmacists, ensuring safe and effective treatment [3]. Group 4: Long-term Health Management - JD Health employs big data analysis to provide personalized health assessments and management recommendations, including dietary adjustments and exercise plans [3]. - The company collaborates with offline pharmacies and medical institutions to create a comprehensive healthcare network, enhancing service accessibility and efficiency [3]. Group 5: Future Directions - JD Health aims to continue innovating service models to provide more professional, convenient, and efficient health services for constipation patients, while promoting standardized diagnosis and management of digestive system diseases [4].

As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. 333-285771 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________ POMDOCTOR LIMITED (Exact name of Registrant as specified in its charter) __________________________ Not Applicable (Translation of Registrant's name into English) __________________________ | Cayman Islands | 7389 | N ...

Core Insights - The company, Ark Health, reported a total revenue of 2.707 billion yuan for 2024, marking an 11.2% year-on-year increase, and an adjusted net profit of 17.119 million yuan, which is a 139% increase compared to 2023, showcasing its enhanced profitability and the effectiveness of AI in the healthcare sector [3][4] - Ark Health focuses on internet-based chronic disease management, providing comprehensive services and has successfully listed on the Hong Kong Stock Exchange, boosting market confidence in the internet and pharmaceutical industries [3][4] - The company aims to maintain high-quality development by leveraging AI technology and innovation, particularly in the Guangdong-Hong Kong-Macao Greater Bay Area [3][4] Financial Performance - Online retail pharmacy services contributed 1.405 billion yuan in revenue, up 8.3%, while customized content and marketing solutions generated 105 million yuan, with a growth rate of 20.7% [4] - The gross margin for comprehensive medical services improved from 15.20% at the end of 2023 to 17.20% at the end of 2024, indicating a focus on sustainable business development [4] - The registered user base for the chronic disease management service platform grew from 42.7 million to 49.2 million, with a monthly active user count rising to 10.1 million, reflecting a 20% year-on-year increase [4][5] Technological Advancements - The company has integrated advanced technologies such as large language models, big data, and cloud computing to enhance its service offerings, including AI doctor assistants and AI customer service assistants [6][7] - The AI doctor assistant can handle over 80% of repetitive inquiries, allowing doctors to focus on complex cases, thereby improving service efficiency and reducing costs [6][7] - The integration of the DeepSeek model and proprietary technology has created a closed-loop service system from hospitals to homes, enhancing the overall healthcare value chain [6][7] Market Position and Strategy - Ark Health has established partnerships with over 1,500 suppliers and 900 pharmaceutical companies, offering approximately 215,000 drug SKUs, with 62% being prescription drugs [4][5] - The company is positioned to strengthen its leading market position in online chronic disease management through strategic initiatives and continuous optimization of its operational tactics [5][6] - The integration of its service platform with medical insurance payment systems has improved user retention and reduced financial burdens on patients, further solidifying its market position [8][9] Industry Impact - The recent inclusion of Ark Health in the Hong Kong Stock Connect is expected to attract more mainland investors, potentially enhancing liquidity and valuation [8] - The company's growth reflects its competitive strength in the internet healthcare sector and contributes to the high-quality development of the biopharmaceutical industry in Guangdong [9] - The supportive policies from the National Health Commission regarding AI applications in healthcare signal a positive outlook for the internet healthcare industry, encouraging further innovation [9]